Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease (COPD)
Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
Listening to breath sounds with the stethoscope/auscultation is used by pulmonary physicians in conjunction with pulmonary function, signs and symptoms, oxygen saturation and diagnostic testing to admit, follow and discharge…
- Trial name
- NCT05661435
- Testing
- RESP Biosensor
- Where
- 2 sites in United States
- Sponsor
- Strados Labs, Inc.
Chronic Obstructive Pulmonary Disease
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v.
- Trial name
- NCT01551316
- Testing
- MN-221
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects with Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT04600778
- Testing
- Cavosonstat 5 mg, Cavosonstat 10 mg, Cavosonstat 25 mg
- Volunteers
- 108 people
- Sponsor
- GSNOR Therapeutics, Inc.
COPD, Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to…
- Trial name
- NCT02937584
- Testing
- GP MDI (PT001) 14.4 μg, FF MDI (PT005) 9.6 μg
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
The purpose of this study is to assess the tolerability and efficacy of inhaled theophylline (ADC4022) on markers of pulmonary inflammation (white blood cells) in induced sputum and in bronchial biopsy samples in subjects with…
- Trial name
- NCT00634413
- Testing
- Theophylline - ADC4022, Budesonide
- Where
- 8 sites in Poland, United Kingdom
- Volunteers
- 91 people
- Sponsor
- Pulmagen Therapeutics
Pulmonary Disease, Chronic Obstructive
Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to establish the lung function effects of added formoterol (12μg QD and BID) during 2-week periods to pharmacodynamic steady state of tiotropium(18μg QD)
- Trial name
- NCT02242240
- Testing
- Formoterol twice daily, Formoterol once daily, Tiotropium once daily
- Volunteers
- 95 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with…
- Trial name
- NCT01525615
- Testing
- Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose)
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Patient Registry of Roflumilast In Real Life
A patient registry to capture real life data and demonstrate the performance of roflumilast (Daxas®) in a standard clinical practice.
- Trial name
- NCT02015767
- Where
- 51 sites in Bulgaria, Greece and 4 more
- Volunteers
- 1,950 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.
- Trial name
- NCT01782326
- Testing
- QVA149, Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
- Where
- 499 sites in Argentina, Austria and 41 more
- Volunteers
- 3,362 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.
- Trial name
- NCT02172378
- Testing
- Tiotropium inhalation capsules
- Volunteers
- 116 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
- Trial name
- PIFR-2 (NCT05165485)
- Testing
- Revefenacin, Tiotropium
- Where
- 76 sites in United States
- Volunteers
- 404 people
- Sponsor
- Theravance Biopharma
Respiratory (Chronic Obstructive Pulmonary Disease)
Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking.
- Trial name
- ALSAC (NCT07315958)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
- Trial name
- INTENSITY (NCT00900731)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 212 sites in United States, Austria and 20 more
- Volunteers
- 1,598 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Vector Engineering Clinical
This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that abolishes tidal expiratory flow limitation (EFL).
- Trial name
- NCT04725500
- Testing
- Auto-Titrating EPAP
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Pulmonary Disease, Chronic Obstructive
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
- Trial name
- NCT00274534
- Testing
- Tiotropium, Salmeterol
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example
Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according…
- Trial name
- NCT01036763
- Where
- 352 sites in Germany
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238171
- Testing
- Atrovent® inhalets
- Volunteers
- 346 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
COPD, Pulmonary Hypertension
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the…
- Conditions
- COPD, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03135860
- Testing
- Inhaled Nitric Oxide 30mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bellerophon
COPD
A COPD Data Registry for Participants With Frequent Exacerbations
This registry will collect data on COPD, including the course of disease, treatment patterns, and potential new therapies. The registry will also track the experience of participants and caregivers in clinical practice.
- Trial name
- AIREIC (NCT07059273)
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.